



## **SpePharm appoints Supervisory Board**

**Amsterdam, The Netherlands, 1 October 2006** - SpePharm Holding, B.V., the specialty pharmaceutical company dedicated to the sales and marketing of innovative hospital and specialists products throughout Europe today announced the appointment of an international Supervisory Board. This follows the launch of SpePharm last month.

SpePharm has strong principles of corporate governance so the Company has appointed only external directors onto the Supervisory Board, with no representatives of the management team. The Supervisory Board consists of four international members:

- Chairman: Dr. Hubert Birner, Partner, TVM Capital
- Director: James C. Gale, Partner, Signet Healthcare Partners (Sanders Morris Harris Group)
- Director: Bernd Seibel, General Partner, CFO European Operations TVM Capital
- Director: Dr David Tierney, CEO of Valera Pharmaceuticals Inc.

Jean-François Labbé, Chief Executive Officer of SpePharm said: "As SpePharm moves forward in the next phase of its corporate development, it is with great delight that I welcome Hubert Birner, James Gale, David Tierney and Bernd Seibel onto our Supervisory Board. They are highly experienced industry professionals and their advice will be invaluable as SpePharm prepares for the commercialization of a first product."

-end-

### **Media contact:**

#### **SpePharm**

**Jean-François LABBE**

Managing Director

Tel: +33 (0) 1 56 60 52 46

[jean-francois.labbe@spepharm.com](mailto:jean-francois.labbe@spepharm.com)

### **About SpePharm Holding, B.V.:**

SpePharm Holding, B.V. is a Dutch company with its registered office in Amsterdam. SpePharm is an emerging pan-European specialty pharmaceutical company focused on the hospital and specialty markets, particularly in oncology, haematology, critical and supportive care and endocrinology. SpePharm was founded in September 2006 by Jean-François Labbé together with leading life science investment firms TVM Capital and Signet Healthcare Partners (part of the Sanders Morris Harris Group). Jean-François Labbé is a former top executive at Hoechst Marion Roussel and Parke Davis with over 30 years of experience in international pharmaceutical management.

For more information about SpePharm, please visit the web site at [www.spepharm.com](http://www.spepharm.com)

## Notes to editors

**Hubert Birner** joined TVM Capital in 2000, and is a General Partner for life sciences in the firm's Munich office. He currently serves as Chairman of the Board of Direvo Biotech AG (Cologne, Germany), Argos Therapeutics Inc (Durham, North Carolina) as well as SpePharm Holding BV. He is also a member of the Board of Directors of Evotec AG (Hamburg, Germany), Jerini AG (Berlin, Germany) and BioXell SA (Milan, Italy), and represents the interests of TVM Capital with Ardana Bioscience plc (Edinburgh, Scotland) and Proteon Therapeutics Inc (Kansas City, Missouri). As a management consultant, he gained extensive experience in R&D management, marketing and sales, and joint venture structuring and business development. Hubert Birner holds an MBA from Harvard Business School and a doctoral degree in biochemistry from Ludwig-Maximilians-University Munich.

**James Gale** is the founding partner of Signet Healthcare Partners, part of the Sanders Morris Harris Group. He initiates investments and provides active management oversight to a number of the portfolio companies. He is currently the Chairman of the Board of Alpex Pharma SA, and also serves on the Board of Directors of Avantium Technologies BV, Cedarburg Pharmaceuticals Inc, Cydex Inc, Indevus Pharmaceuticals, Inc, and Molecular Medicine BioServices Inc, as well as SpePharm BV. Prior to founding Signet Healthcare Partners, James Gale was head of principal investment activities and head of investment banking for Gruntal & Co., LLC.

**Bernd Seibel** joined TVM Capital in 1993, and serves as General Partner and CFO of the firm's European operations. Bernd Seibel serves on the board of alfabet meta-modeling AG, Berlin, and Noxxon Pharma AG, Berlin in addition to SpePharm BV. Bernd Seibel is actively involved in TVM Capital's fundraising activities as well as in all European IPOs of TVM Capital portfolio companies. He serves as Chairman of the EVCA (European Venture Capital Association) Reporting Guidelines Working Group and is a member of the tax and legal committee at BVK, the German Venture Capital Association. Prior to joining TVM Capital, he served as Manager of Mergers & Acquisition and as an auditor at KPMG Deutsche Treuhand-Gesellschaft. He earned a degree in business administration at the University of Cologne.

**David S Tierney, MD**, joined Valera in August 2000 as President and Chief Executive Officer. Prior to joining Valera Dr. Tierney was president of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company. Prior to Biovail, Dr. Tierney spent three years at Roberts Pharmaceutical Corporation as senior vice president of drug development from March 1997 to January 2000. Prior to joining Roberts, Dr. Tierney spent eight years at Elan Corporation, plc, a pharmaceutical company, in a variety of management positions. Dr. Tierney currently serves as a director on the boards of Able Laboratories, a pharmaceutical company, and Catalyst Pharmaceutical Partners. Dr. Tierney received a medical degree from the Royal College of Surgeons in Dublin, Ireland and subsequently trained in internal medicine.